Keylika

Redefining the Standard of Care for Iron Deficiency Anemia

Keylika is active in the healthcare space based in Walnut Creek, CA, USA, founded in 2022.

Profile

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.

Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

The company sits in the healthcare segment, where it competes on its core product or service.

The company is recorded as being based in Walnut Creek, CA, USA.

The company is listed at the Summer 2022 stage of development.

Recorded headcount: 1 employees.

Website: www.keylika.com